drugset
drugset / Trial / NCT06392659

A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults

NCT06392659 ↗

Phase 1 Completed 42 enrolled Vertex Pharmaceuticals Incorporated
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK), drug-drug interaction, and safety and tolerability of VX-993 in healthy participants.

Timeline

Start
2024-05-02
Primary completion
2024-07-02
Completion
2024-07-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemfibrozil Small molecule — Oral
Subject Itraconazole Small molecule — Oral
Subject Midazolam Small molecule — Oral
Subject VX-993 Unknown — Oral

Indications

No indication recorded.